Psych Congress
Sept 15-19
New Orleans, LA
Tardive Dyskinesia
Clinician- and Patient-Reported Outcomes With Untreated Tardive Dyskinesia: 24-Month Interim Analysis of the IMPACT-TD Registry
Authors:
Richard Jackson, Martijn Konings, Diana Klakotskaia, Mark Henegar, Vidhya Selvaraj
Healthcare Professional Preferences for Vesicular Monoamine Transporter 2 Inhibitor Treatment of Tardive Dyskinesia: A Discrete Choice Experiment
Authors:
Brian Chen, Diana Klakotskaia, Tommi Tervonen, Stephane Deparis
Long Acting Injectable
Joint Population Pharmacokinetic Model of Oral, Intramuscular, and Subcutaneous (TV-44749) Olanzapine to Support TV-44749 Dosing and Switching Strategies
Authors:
Nikunjkumar Patel, Henning Schmidt, Itay Perlstein, Avia Merenlender-Wagner, Anna Elgart, Rajendra Singh
Population Pharmacokinetic Simulations of Inpatient Switching From Oral or Short-Acting Intramuscular Olanzapine to TV-44749
Authors:
Nikunjkumar Patel, Itay Perlstein, Jonathan Meyer, Ilan Melnick, Harissh Chandrasekaran, Nikita Ramwani, Sharath Kumar, Vijay Ivaturi, Rolf Hansen, Avia Merenlender Wagner, Arti Phatak, Rajendra Singh
Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Efficacy Results From the Phase 3 SOLARIS Trial
Authors:
Christoph U. Correll, Rotem Gidron-Budovsky, Tamar Bar-Nur, Nir Sharon, Kelli R. Franzenburg, Anna Elgart
Durability of Response With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Schizophrenia: Post Hoc Analysis of the Phase 3 SOLARIS Trial
Authors:
Christoph U. Correll, Tamar Bar-Nur, Kelli R. Franzenburg, Noam Mairon, Anat Piotraut, Anna Elgart
Characterization of the Body Weight and Metabolic Profile of Subcutaneous Long-Acting Injectable Olanzapine (TV-44749): Results From the Phase 3 SOLARIS Trial
Authors:
Christoph Correll, Rotem Gidron-Budovsky, Tamar Bar-Nur, Nir Sharon, Kelli R. Franzenburg, Anat Piotraut, Helena Knebel, Noam Mairon, Katja Sagalovich, Anna Elgart
Real-World Healthcare Resource Utilization and Costs Among Adults With Schizophrenia Receiving TV-46000 Versus Paliperidone Palmitate Once-Monthly
Authors:
Ayush Patel, Arti Phatak, Siddhi Korgaonkar, Elizabeth "Lizzi" Esterberg, Ravi K Goyal, Ying Zhang, Ayelet Yaari
Real-World Treatment Patterns and Healthcare Resource Utilization With TV-46000 Versus Other Long-Acting Injectable Antipsychotics
Authors:
Ayush Patel, Arti Phatak, Ayelet Yaari, Ying Zhang, Siddhi Korgaonkar, Lizzi Esterberg, Ravi Goyal
Real-World Effectiveness of Switching from Oral Antipsychotics to TV-46000, a Long-Acting Subcutaneous Risperidone Formulation, or Another Oral Antipsychotic in Patients with Bipolar I Disorder
Authors:
Arti Phatak, Zenobia Dotiwala, Essy Mozaffari, Julian Casciano, Ayush Patel, Ying Zhang, Rolf T. Hansen, Ayelet Yaari, Mark Suett, Jennifer Parish, Roger S. McIntyre
This site is intended for US Healthcare Professionals only
NPS-US-NP-01222 | February 2024